Introduction
Early clues that the Epstein-Barr virus (EBV) may play a role in the etiology of Hodgkin lymphoma came from seroepidemiologic case-control studies showing that Hodgkin lymphoma cases had altered antibody titers against the EBV viral capsid antigen (VCA) and early antigen (EA) complex, relative to population controls. 1 In 1989, we reported that this altered serologic profile of EBV preceded the development of Hodgkin lymphoma by several years. 2 Further, we found that this pattern involved not only elevated antibodies to VCA and the EA complex, antigens expressed in the lytic cycle, but also elevated antibodies to the EBV nuclear antigen (EBNA) complex expressed in latency. These findings were subsequently confirmed in a report by Lehtinen et al. 3 Since that time, reliable assays have been developed to detect antibodies against subcomponents of the EBNA complex, 4 which have helped to further characterize the host response to EBV. Typically, patients with primary EBV infection that results in infectious mononucleosis first develop antibodies against VCA, EA, and the latent protein EBNA-2. This pattern is followed by the appearance of antibodies to EBNA-1. Antibodies against EBNA-2 subsequently diminish, resulting in an anti-EBNA-1/anti-EBNA-2 antibody ratio of Ͼ 1.0 in healthy carriers. 5 Persistent anti-EBNA-1/anti-EBNA-2 antibody ratios of Յ 1.0 have been described in patients with inherited immunologic disorders, severe infectious mononucleosis, chronic EBV infection, rheumatoid arthritis, chronic renal failure, and AIDS. [4] [5] [6] [7] [8] [9] Recently, it has been shown that an anti-EBNA-1/EBNA-2 ratio Յ 1.0 is associated with Hodgkin lymphoma risk, independent of a history of infectious mononucleosis. 10 Henle et al have suggested that this atypical pattern is indicative of inadequate host regulation of latent EBV infection. 5 In 20%-50% of Hodgkin lymphoma cases overall, EBV nucleic acids and proteins are detected in the diagnostic Hodgkin and Reed-Sternberg cells. 11, 12 These cells express several viral proteins that have been implicated in transformation in various model systems. [13] [14] [15] The detection of EBV in a variable proportion of cases worldwide raises several alternative models for Hodgkin lymphoma pathogenesis. These include a model in which EBV plays a pathogenic, early role in almost all of Hodgkin lymphoma, and the genome is somehow lost from some patients' lesions in concert with a more favorable immune response to the virus, leaving no viral "footprint" behind. Alternatively, there may be 2 independent causal pathways in the etiology of Hodgkin lymphoma, with EBV involved only in the pathogenesis of EBV ϩ Hodgkin lymphoma cases and other factors involved in EBV Ϫ cases. 16, 17 Our strategy to clarify the relative likelihood of these hypotheses was to compare the prediagnosis EBV serologic response in EBV ϩ and EBV Ϫ Hodgkin lymphoma cases to determine whether antibody profiles against viral antigens differ based on EBV presence in tumor cells. We therefore conducted a nested-case control study within a cohort of active-duty military personnel with archived serum samples collected several years before Hodgkin lymphoma diagnosis. In addition to case-control comparisons, the EBV antibody profile of EBV ϩ Hodgkin lymphoma cases was The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ''advertisement'' in accordance with 18 USC section 1734.
3750
BLOOD, 1 NOVEMBER 2012 ⅐ VOLUME 120, NUMBER 18 For personal use only. on April 10, 2017. by guest www.bloodjournal.org From compared with that of EBV Ϫ cases to determine whether there was heterogeneity in the serologic response between the 2 groups.
Methods

Study population
All patients with a new diagnosis of Hodgkin lymphoma (ICD-9 201) identified from January 1, 1990, through December 31, 1999, among active-duty military personnel with an archived serum specimen in the DoD Serum Repository drawn before the diagnosis date were eligible for inclusion in the study. Two military data sources, the Automated Centralized Tumor Registry and the Defense Medical Surveillance System, were queried to identify incident cases. Defense Medical Surveillance System capabilities include linking persons identified from various demographic and medical databases to serum specimens archived in the DoD Serum Repository. 18 We identified 473 potential cases with confirmed pathology reports and serum specimens archived in the DoD Serum Repository. Of these, we were able to retrieve tissue blocks for 308 cases (65%) from anatomic pathology departments in 62 military hospitals worldwide and from the National Pathology Repository at the Armed Forces Institute of Pathology. Prediagnosis serum samples from 160 cases with tissue blocks were retrieved from the repository for this analysis. Of these cases, pathology review could not confirm the diagnosis of 4 cases, detection of the tumor EBV was indeterminate for 16 cases, and restriction to classic Hodgkin lymphoma eliminated 11 cases of nodular lymphocyte predominance subtype. In addition, 1 case was excluded because of inconclusive serologic results. Complete data including EBV tumor status were thus available for 128 cases.
We attempted to match each case with 3 controls by age (Ϯ 1 year), sex, race, and ethnic group (white non-Hispanic, black non-Hispanic, Hispanic, Asian, or other), and date of serum collection (Ϯ 30 days). To achieve risk set sampling, whereby controls were selected at random from the group at risk to become a case in a given time period, 19 controls were required to be on active duty on the matched case's diagnosis date.
Serologic specimens and assays
The DoD Serum Repository is currently the world's largest serum repository, with Ͼ 40 million specimens collected from ϳ 9 million people since 1985. 18 The repository was originally established for the purpose of storing excess sera from the Armed Forces HIV testing program. Since that time, the repository has expanded to include specimens from service members deployed overseas. 18 Specimens are stored at Ϫ30°C in walk-in freezers. All samples that are available for study in the DoD Serum Repository are HIV-antibody negative.
Study serum specimens were shipped frozen to Virolab Inc. All serologic tests were performed in a blinded fashion. Case and control specimens were randomly mixed within each batch of serum samples sent for testing. In addition, matched case-control sets were analyzed together in the same run of any given assay. Immunoglobulin G (IgG) antibodies to EBV VCA and EA complex (diffuse [EA-D] and restricted [EA-R]) were measured using immunofluorescence. 5 If a person had detectable titers to both EA-D and EA-R, the higher value was classified as the titer against the EA complex. IgG antibodies against the EBNA complex and 2 of its subcomponents, EBNA-1 and EBNA-2, were determined using anticomplement immunofluorescence. 4 The EBV Ϫ BJAB cell line was used as a control. 4, 5 The value for a titer was considered as the highest of serial 2-fold dilutions to register a positive reaction. Cases and controls were considered as EBV-seropositive if the IgG antibody titer to VCA was Ն 1:20 or if the IgG antibody titer to EBNA-1 was Ն 1:5 and antibodies to BJAB were not detected. An elevated titer was defined a priori as the upper 15% (or nearest cut-off) of the distribution of each antibody among controls. The minimal values of elevated titers were as follows: anti-VCA: Ն 1:2560, anti-EA complex: Ն 1:40, anti-EBNA complex Ն 1:1280, anti-EBNA-1: Ն 1:1280, and anti-EBNA-2: Ն 1:80. The anti-EBNA-1/anti-EBNA-2 ratio also was examined, with a ratio of Յ 1.0 considered as serologic evidence of a deregulated immune response in other clinical settings. [4] [5] [6] [7] [8] [9] Masked repeat samples (5% of specimens) were included to enable monitoring of within-batch reproducibility of antibody titers. The withinbatch coefficients of variation from the blind quality control samples were 9.9% for anti-VCA, 38.9% for anti-EA complex, 12.4% for anti-EBNA complex, 16.8% for anti-EBNA-1, and 37.5% for anti-EBNA-2.
Histopathologic classification and detection of EBV in tumor tissue
The 2001 World Health Organization Classification of Hematopoietic and Lymphoid Tumors was used to classify the following subtypes of classic Hodgkin lymphoma: nodular sclerosis, mixed cellularity, lymphocyte depletion, and classic Hodgkin lymphoma, not further classified. 20 Tumors were evaluated for EBV using in situ hybridization to detect viral transcripts (EBERs) 21, 22 and immunohistochemistry to detect latent membrane protein-1 in Hodgkin and Reed-Sternberg cells and their variants. 15 Cases scored positive for either EBERs or latent membrane protein-1 were considered as EBV ϩ Hodgkin lymphoma. Cases were defined as EBV Ϫ Hodgkin lymphoma if both assays were negative or if information from only 1 assay was available and the result was negative. 23 
Statistical analysis
Statistical analysis was performed using SAS Version 8.01 (SAS Institute). P values were 2-tailed, and tests of statistical significance were based on an ␣ level of .05. Among EBV seropositives, median antibody titers were compared using the Wilcoxon rank-sum test. Conditional logistic regression for matched data was used to compute the relative risk (RR), estimated by the odds ratio (OR), of Hodgkin lymphoma associated with the prevalence of detectable antibody or an elevated EBV antibody level, the 95% confidence interval (CI) around the relative risk, and the corresponding P value estimated using the Wald 2 test. For case-case comparisons to examine the heterogeneity of the serologic response to EBV between the 2 case groups, unconditional logistic regression was performed controlling for age (18-22 years, 23-26 years, Ͼ 26 years); sex; race (white, nonwhite); and year of serum collection (1988-1991, 1992-1994, 1995-1998) . 24 We controlled for potential confounding by histology (nodular sclerosis, mixed cellularity, other histology) in multivariate models.
The research protocol was approved by the institutional review boards of the Walter Reed Army Institute of Research, the Harvard School of Public Health, and the Johns Hopkins School of Medicine. The study was conducted in accordance with the Declaration of Helsinki.
Results
Of the 128 cases of Hodgkin lymphoma in this analysis, 40 (31.3%) had EBV detected in tumor cells and 88 (68.7%) did not. The median age at diagnosis was 24 years (range, 18-49 years); ϳ 90% of the study subjects were male and 78% were white (Table 1) . In general, EBV ϩ Hodgkin lymphoma cases were more likely than EBV Ϫ Hodgkin lymphoma cases to be younger and white and less likely to be of nodular sclerosis subtype.
Based on either the earliest serum specimen or the specimen drawn at least 2 years after the first serum sample for persons who were initially seronegative, 100% of the EBV ϩ Hodgkin lymphoma cases, 89.8% of the EBV Ϫ cases, and 92.4% of the controls were EBV-seropositive before diagnosis. As shown in Table 2 , all EBV ϩ Hodgkin lymphoma cases, but not all EBV Ϫ cases or controls, had detectable IgG antibody titers to VCA or EBNA complex, indicating an established EBV infection. The prevalence of detectable antibody titers was significantly higher in EBV ϩ Hodgkin lymphoma cases compared with their matched controls for anti-EA complex (RR ϭ 2.5; 95% CI, 1.1-5.8) and anti-
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EBNA-2 (RR ϭ 2.5; 95% CI, 1.1-5.8), and the anti-EBNA-1/anti-EBNA-2 antibody ratio was significantly more likely to be Յ 1.0 (RR ϭ 4.7; 95% CI, 1.6-13.8). No significant differences, however, were noted in the prevalence of any of the antibody titers comparing EBV Ϫ Hodgkin lymphoma cases with their matched controls. The prevalence of an anti-EBNA-1/anti-EBNA-2 antibody ratio of Յ 1.0 was 28.2% in EBV ϩ Hodgkin lymphoma cases and markedly lower in both EBV Ϫ Hodgkin lymphoma cases (3.8%) and controls (9.2%).
We also examined median antibody titers in the 2 case groups and in controls ( Table 2) . Median titers were significantly higher among EBV ϩ Hodgkin lymphoma cases than among their matched controls for IgG against VCA (P ϭ .01) and EA complex (P ϭ .03). The EBV ϩ cases also had a significantly lower median anti-EBNA- 1/anti-EBNA-2 antibody ratio (P ϭ .03). No significant differences in any of the median antibody titer levels were found for EBV Ϫ Hodgkin lymphoma cases compared with their matched controls. Overall, median titers were strikingly similar in EBV Ϫ Hodgkin lymphoma cases compared with all controls, and both groups had lower median levels than EBV ϩ cases. The notable exception was for anti-EBNA-1, for which EBV Ϫ cases had the highest median titer of the 3 groups. In case-case comparisons, EBV ϩ cases also had a significantly lower median anti-EBNA-1/ anti-EBNA-2 antibody ratio compared with EBV Ϫ cases (P ϭ .004).
In analyses of the 40 EBV ϩ Hodgkin lymphoma cases and matched controls, a statistically significant increased risk was associated with elevated anti-VCA IgG (RR ϭ 3.1; 95% CI, 1.1-8.7) and the low anti-EBNA-1/anti-EBNA-2 ratio (RR, 4.7; 95% CI, 1.6-13.8). Analyses of 88 EBV Ϫ Hodgkin lymphoma cases relative to their matched controls revealed a different pattern, as null associations were found with all antibody titers and with a low antibody ratio (Table 3) .
Case-case comparisons were performed in addition to EBVstratified case-control comparisons to determine whether the risk associated with an altered EBV antibody profile differed between EBV ϩ and EBV Ϫ Hodgkin lymphoma cases, controlling for age, sex, race, year of serum collection, and histology. The only antibody titer with a case-case RR that differed statistically from the null was a low anti-EBNA-1/anti-EBNA-2 antibody ratio (RR ϭ 14.0; 95% CI, 2.7-72.5 for EBV positivity; Table 3 ). This association remained the same with additional mutual control of antibodies to the other antigens (RR ϭ 14.2; 95% CI, 2.7-74.2 for EBV positivity; Table 4 ).
We performed exploratory analyses using serial samples (N ϭ 11 EBV ϩ cases with Ն 2 serum samples) and stratified by time between serum collection and diagnosis, but results were statistically unstable (data not shown).
Discussion
Our findings, the first to be based on prediagnosis serology, indicate that the EBV antibody profile differs by the detection of EBV in tumor cells of Hodgkin lymphoma cases, with EBV ϩ cases displaying a distinctly atypical pattern compared with either EBV Ϫ cases or controls. Among the EBV ϩ Hodgkin lymphoma cases compared with matched controls, we found evidence of elevated IgG antibody titers against VCA and EA complex and a higher prevalence of a low anti-EBNA-1/anti-EBNA-2 antibody ratio. The low antibody ratio was the indicator most strongly associated with EBV positivity, controlling for the other EBV antibody titer levels. EBV Ϫ cases, however, had a serologic pattern that closely resembled that of controls without Hodgkin lymphoma.
The determinants of humoral immunity to viral antigens remain incompletely understood. EBV infection, however, is lifelong, and patterns of viral gene expression differ among cell and tissue types, as well as among EBV-associated tumors. VCA and EA are antigens that are expressed in lytic but not in latent EBV infection. Thus, one possible interpretation of higher IgG titers to these antigens in patients with EBV-associated Hodgkin lymphoma is that these patients have increased exposure to lytic antigens, perhaps as a result of increased viral lytic replication (in normal or neoplastic tissues). Similarly, low anti-EBNA-1/anti-EBNA-2 antibody ratios may reflect the presence of a cell population in vivo expressing EBNA-1 and EBNA-2. EBV-immortalized lymphocytes in vitro express both of these antigens; however, in vivo EBNA-2 expression in peripheral blood lymphocytes has not been documented except in the setting of recent primary infection or in immunocompromised patients. EBV-associated Hodgkin lymphoma expresses EBNA-1 but not EBNA-2, so it seems unlikely Data are RR (95% CI). NA indicates not applicable. *Unconditional logistic regression with mutual control for antibodies to VCA, EA complex, EBNA-1, EBNA-2, and adjusted for age, sex, race, year of serum collection, and histology.
†Unconditional logistic regression with mutual control for antibodies to VCA, EA complex, EBNA-1/EBNA-2 ratio Յ 1.0, and adjusted for age, sex, race, year of serum collection, and histology. ‡Elevated titer levels.
EBV SEROLOGY AND EBV-POSITIVE HODGKIN LYMPHOMA 3753 BLOOD, 1 NOVEMBER 2012 ⅐ VOLUME 120, NUMBER 18 For personal use only. on April 10, 2017. by guest www.bloodjournal.org From that Hodgkin tumor cells per se account for this humoral response. Given that these tumors do express EBNA-1, however, it is notable that EBV ϩ Hodgkin lymphoma cases were more likely than EBV Ϫ cases to have detectable and elevated EBV antibody titers, except against the latent nuclear antigen EBNA-1.
In a population-based case-control study of Hodgkin lymphoma with blood specimens obtained after diagnosis, a marginally statistically significant OR of 1.9 (95% CI, 0.9-4.0) was found with a low anti-EBNA-1/anti-EBNA-2 antibody ratio, comparing EBV ϩ with EBV Ϫ cases. 25 In another case-case comparison of 27 EBV ϩ Hodgkin lymphoma cases relative to 80 EBV Ϫ cases, Enblad et al found that the prevalence of detectable titers and elevated titers for anti-VCA IgG and anti-EBNA-2 were associated with EBV positivity, 26 although none of the associations were statistically significant.
The strengths of our study stem from our ability to assess subcomponents of the EBNA complex in prediagnosis serology in EBV ϩ and EBV Ϫ Hodgkin lymphoma cases. A limitation is the relatively small sample size, which precluded a statistically robust analysis stratified by time to diagnosis or based on serial samples. Analyses stratified by histologic subtypes of classic Hodgkin lymphoma rather than tumor EBV status also were not robust as there were only 21 cases of mixed cellularity subtype. Moreover, because our study population was composed mainly of young men, these results may not be generalizable to other age groups or to women. Of note, 31% of our Hodgkin lymphoma cases were EBV ϩ , a prevalence similar to that found in other comparable populations. 12 The hypothesis that EBV may be involved in all of Hodgkin lymphoma and is somehow lost in a subset of cases was suggested by reports of the loss of EBV in Burkitt lymphoma cell cultures. 27, 28 Sixbey has proposed that immune selection may lead to the loss of the EBV episome in Burkitt lymphoma that is seen in economically developed populations, implicating a hit-and-run role for the virus. 29 It also has been speculated that the hit-and-run model may explain the pathogenesis of EBV Ϫ Hodgkin lymphoma. 30, 31 Our findings show that people who will develop EBV Ϫ Hodgkin lymphoma do not differ from control populations in their EBV serology. Although this does not exclude the possibility that the virus might be lost from tumor cells, our results do not provide any support for this hypothesis.
Our findings, however, do suggest a distinctive immune response to EBV infection in patients destined to develop EBV ϩ Hodgkin lymphoma. There are a number of other reports in the literature that may bear on the immune response to EBV in patients with EBV ϩ Hodgkin lymphoma. It has been established that the increased risk associated with symptomatic primary EBV infection (manifested as infectious mononucleosis) is found only in EBV ϩ , but not EBV Ϫ Hodgkin lymphoma. 32 Genetic variations in the HLA class I region appear to be specifically associated with EBV ϩ Hodgkin lymphoma. [33] [34] [35] Increased copy number of EBV-DNA in blood of patients with EBV ϩ Hodgkin lymphoma has been documented. 36 And, provocatively, a decreased frequency of T cells expressing IL-15 receptor ␣ after symptomatic infectious mononucleosis has been reported, 37 although a subsequent investigation called the observation into question. 38 Our novel finding that a prediagnosis abnormal serologic response to EBV latent antigens is restricted to EBV ϩ Hodgkin lymphoma may provide further clues to the character of the immune dysregulation associated with the pathogenesis of this disease.
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